Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016)
Protagonist Therapeutics (PTGX) reported Preferred Stock Liabilities of $66.6 million for Q2 2016, up 80.05% sequentially from $37.0 million in Q4 2015.
Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Protagonist Therapeutics (PTGX) has 2 years of Preferred Stock Liabilities data on file, last reported at $66.6 million in Q2 2016.
- For the quarter ending Q2 2016, Preferred Stock Liabilities changed N/A year-over-year to $66.6 million; the trailing twelve-month figure through Jun 2016 stood at $66.6 million (changed N/A YoY), and the FY2015 full-year result was $37.0 million, up 79.8% from the prior year.
- Preferred Stock Liabilities grew to $66.6 million in Q2 2016, from $37.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $66.6 million in Q2 2016 to a low of $37.0 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 66.61 Mn |
| Dec 31, 2015 | 37.00 Mn |